Business · 29/05/2026
FDA Renews Psychopharmacologic Drugs Advisory Committee for 2 Years
The FDA has renewed the Psychopharmacologic Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on June 4, 2028.
Business · 29/05/2026
The FDA has renewed the Psychopharmacologic Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on June 4, 2028.
Explore insights